This pharma bluechip is springing back to life. Is it worth your consideration?

To a long-term Lupin investor, turbulence is all too familiar. A glance at its financial accounts would reveal the many challenges it has faced over the last decade, including but not limited to losses, write-offs and litigations. However, the generic drug maker (off-patent drugs) is restoring its health. In the latest financial year (FY24), its operating profit grew over three times and the company clocked an operating profit margin of 13 per cent, highest since FY18. Financials at a glance FY24 marks healthy recovery for Lupin after years of inconsistency FY24 FY23 FY22 FY21 FY20 FY19 Revenue (Rs crore) 19,656 16,642 16,405 15,163 15,375 14,665 EBIT (Rs crore) 2,596 840 -1,443 1,679 1,385 1,715 PAT (Rs crore) 1,936 448 -1,509 1,228 -400 521 EBIT margin (%) 13.2 5 -8.8 11.1 9 11.7 ROE (%) 13.9 6.1 -7.1 9.7 5.5 8 The market has also